AMGN241004C340000
- 0.05
- -0.06-54.55%
Amgen Newsroom
Amgen (AMGN) Rose Owing To The Announcement Of Promising Data For Its Novel Medication
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
U.S. Tweaks 2025 Medicare Price Negotiation Process
Amgen (NASDAQ:AMGN) Has A Somewhat Strained Balance Sheet
Eli Lilly and Co (LLY.US) explores new uses for 'weight-loss miracle drug' Zepbound, aiming to reduce the incidence of high-risk populations such as diabetes.
eli lilly and co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Express News | La La Anthony Partners With Amgen to Share Candid, Behind-the-Scenes Look at How Plaque Psoriasis Affects Her Life
(AMGN) - Analyzing Amgen's Short Interest
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales
Institutional Investors May Overlook Amgen Inc.'s (NASDAQ:AMGN) Recent US$7.9b Market Cap Drop as Long-term Gains Remain Positive
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Notable Analyst Calls This Week: Microsoft, Starbucks and GM Among Top Picks
Federman & Sherwood Investigates Amgen, Inc. for Data Breach
Chevron, Visa Share Gains Contribute To Dow's Nearly 325-Point Climb
Cantor Highly Bullish on Amgen Obesity Drug, Starts Coverage at Overweight
Cantor Fitzgerald Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $405
Amgen Inc. (AMGN): An Undervalued Wide Moat Stock to Buy According to Analysts
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why